Aspire BioPharma, Inc. (ASBP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aspire BioPharma, Inc. (ASBP) has a cash flow conversion efficiency ratio of -0.785x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.04 Million) by net assets ($3.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ASBP defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Aspire BioPharma, Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Aspire BioPharma, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aspire BioPharma, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aspire BioPharma, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Baijiayun Group Ltd
NASDAQ:RTC
|
-1.214x |
|
UNITH LTD.
F:CM30
|
N/A |
|
Iceni Gold Ltd
AU:ICL
|
-0.017x |
|
Torr Metals Inc
V:TMET
|
-0.067x |
|
Rochester Resources Ltd
V:RCT
|
-0.031x |
|
Nexalin Technology Inc.
NASDAQ:NXL
|
-0.593x |
|
Companhia Paranaense de Energia Pref ADR
NYSE:ELP
|
0.030x |
|
Nordic LEVEL Group AB
ST:LEVEL
|
0.057x |
Annual Cash Flow Conversion Efficiency for Aspire BioPharma, Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Aspire BioPharma, Inc. from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see ASBP company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-6.38 Million | $-4.92 Million | 0.772x | +348.43% |
| 2024-12-31 | $-1.54 Million | $-265.19K | 0.172x | +616.19% |
| 2023-12-31 | $19.58 Million | $-653.11K | -0.033x | -584.45% |
| 2022-12-31 | $289.07 Million | $-1.41 Million | -0.005x | -100.89% |
| 2021-12-31 | $-475.00 | $-260.00 | 0.547x | -- |
About Aspire BioPharma, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually admi… Read more